Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

BACKGROUND: Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers. METHODS: In this multicenter, prospective, open-label, single-group study, we evaluated 67 patients who had acute major bleeding within 18 hours after the administration of a factor Xa inhibitor. The patients all received a bolus of andexanet followed by a 2-hour infusion of the drug. Patients were evaluated for changes in measures of anti-factor Xa activity and were assessed for clinical hemostatic efficacy during a 12-hour period. All the patients were subsequently followed for 30 days. The efficacy population of 47 patients had a baseline value for anti-factor Xa activity of at least 75 ng per milliliter (or ≥0.5 IU per milliliter for those receiving enoxaparin) and had confirmed bleeding severity at adjudication. RESULTS: The mean age of the patients was 77 years; most of the patients had substantial cardiovascular disease. Bleeding was predominantly gastrointestinal or intracranial. The mean (±SD) time from emergency department presentation to the administration of the andexanet bolus was 4.8±1.8 hours. After the bolus administration, the median anti-factor Xa activity decreased by 89% (95% confidence interval [CI], 58 to 94) from baseline among patients receiving rivaroxaban and by 93% (95% CI, 87 to 94) among patients receiving apixaban. These levels remained similar during the 2-hour infusion. Four hours after the end of the infusion, there was a relative decrease from baseline of 39% in the measure of anti-factor Xa activity among patients receiving rivaroxaban and of 30% among those receiving apixaban. Twelve hours after the andexanet infusion, clinical hemostasis was adjudicated as excellent or good in 37 of 47 patients in the efficacy analysis (79%; 95% CI, 64 to 89). Thrombotic events occurred in 12 of 67 patients (18%) during the 30-day follow-up. CONCLUSIONS: On the basis of a descriptive preliminary analysis, an initial bolus and subsequent 2-hour infusion of andexanet substantially reduced anti-factor Xa activity in patients with acute major bleeding associated with factor Xa inhibitors, with effective hemostasis occurring in 79%. (Funded by Portola Pharmaceuticals; ANNEXA-4 number, NCT02329327 .).

Full Text

Duke Authors

Cited Authors

  • Connolly, SJ; Milling, TJ; Eikelboom, JW; Gibson, CM; Curnutte, JT; Gold, A; Bronson, MD; Lu, G; Conley, PB; Verhamme, P; Schmidt, J; Middeldorp, S; Cohen, AT; Beyer-Westendorf, J; Albaladejo, P; Lopez-Sendon, J; Goodman, S; Leeds, J; Wiens, BL; Siegal, DM; Zotova, E; Meeks, B; Nakamya, J; Lim, WT; Crowther, M; ANNEXA-4 Investigators,

Published Date

  • September 22, 2016

Published In

Volume / Issue

  • 375 / 12

Start / End Page

  • 1131 - 1141

PubMed ID

  • 27573206

Pubmed Central ID

  • PMC5568772

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1607887


  • eng

Conference Location

  • United States